Amgen stock extends focus on earnings and guidance

Amgen Inc. (US0311621009) is being read through the lens of its latest reported numbers: $9.1 billion in first-quarter 2026 revenue and $2.15 in adjusted diluted EPS. The company also said 2025 revenue reached $33.4 billion, giving investors a dated reference point for scale and profitability.

Q1 2026 revenue at $9.1 billion

The first-quarter 2026 revenue figure of $9.1 billion matters because it offers the cleanest fresh operating snapshot available here. In the same period, adjusted diluted EPS came to $2.15, and both numbers frame how much cash-generating power Amgen still has in a single quarter.

That combination is especially useful for comparing the business with its own earlier base. Revenue at $9.1 billion and EPS at $2.15 in Q1 2026 can be measured against the full-year 2025 revenue base of $33.4 billion, which signals a large recurring commercial engine rather than a one-off quarter.

2025 revenue reached $33.4 billion

Amgen reported 2025 revenue of $33.4 billion, which gives a full-year benchmark for the stock story beyond a single earnings print. The comparison is straightforward: a $9.1 billion first quarter in 2026 sits within a business that already produced $33.4 billion for the prior year.

For investors, the margin question is the one that follows naturally from those figures. Amgen has not been presenting itself as a pure growth story alone; the key is whether the company keeps turning that revenue base into durable earnings, with Q1 2026 adjusted EPS at $2.15 as the latest visible datapoint.

Revenue base and earnings power

The product side matters because Amgen is still anchored by large branded therapies and a broad portfolio of biologics. In practical terms, the stock tends to move with confidence in the durability of that portfolio, not just with one quarter of sales.

That is why the revenue and EPS figures matter more than generic business descriptions. A company with $33.4 billion in 2025 revenue and $2.15 in adjusted EPS in Q1 2026 is being judged on consistency, pricing power, and the ability to protect cash generation.

Closing price context

Amgen stock remains tied to those published fundamentals rather than a single headline move. The latest evidenced numbers in this article are the Q1 2026 revenue of $9.1 billion, adjusted diluted EPS of $2.15, and 2025 revenue of $33.4 billion.